Eli Lilly reported the first Phase 3 data for its oral GLP-1 orforglipron Thursday morning, saying the drug succeeded in a type 2 diabetes trial. The drug hit the primary endpoint of lowering A1C by …
Clinical results of a GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable drugs.
Lilly, which makes weight loss injections, unveils trial result showing Type 2 diabetes sufferers lost 8% of body weight taking GLP-1 drug in tablet form – and millions could soon get them
Daily Pill May Work as Well as Ozempic for Weight Loss and Blood Sugar The New York Times Eli Lilly’s weight loss pill succeeds in first late-stage trial on diabetes patients CNBC Lilly’s oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial Eli Lilly and … Read more
A DAILY weight loss pill that works like Ozempic has passed a full clinical trial for the first time. Orforglipron is made by Lilly which manufactures the ‘King Kong’ of fat jabs, Mounjaro. AlamyA daily weight loss pill could work like Ozempic (stock image)[/caption] A trial has found diabetic patients taking it without dieting lost … Read more
The drug helped lower blood sugar and cut an average of 16 pounds The first GLP-1 weight-loss pill is a step closer to hitting the market. Eli Lilly said its experimental pill met its goals in a pivotal study, helping diabetes patients lower blood sugar—and even reduce weight, bringing an oral …
A daily pill from Eli Lilly helped patients with type 2 diabetes improve their blood sugar and shed weight, the company said Thursday, results that could propel the next-generation treatment onto the market. The drug, orforglipron, produced results that were nearly comparable to the benefits of available GLP-1 drugs, which are weekly injectable treatments. Companies … Read more
Eli Lilly has met its goal of achieving semaglutide-like efficacy with an oral GLP-1 drug. The phase 3 study linked the oral GLP-1 drug orforglipron to similar reductions in blood glucose and body weight to Novo Nordisk’s injectable blockbuster, although the figures are down on Lilly’s midphase data.
